Upgrade to SI Premium - Free Trial

FBR Capital Recommends Buying Anavex Life Sciences (AVXL) After Yesterday's Weakness

July 28, 2016 7:45 AM
FBR Capital analyst Christopher James reiterated his Outperform rating and $10 price target on Anavex Life Sciences (NASDAQ: AVXL) following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA

Next Articles